Published in J Gen Virol on February 01, 2008
Diagnostic algorithm for HBV safe transfusion. Blood Transfus (2009) 1.08
Disparate distribution of hepatitis B virus genotypes in four sub-Saharan African countries. J Clin Virol (2013) 0.89
Hepatitis B virus (HBV) infection and recombination between HBV genotypes D and E in asymptomatic blood donors from Khartoum, Sudan. J Clin Microbiol (2010) 0.89
Characterization of occult hepatitis B virus infection from blood donors in China. J Clin Microbiol (2011) 0.89
HBV vaccine efficacy and detection and genotyping of vaccineé asymptomatic breakthrough HBV infection in Egypt. World J Hepatol (2011) 0.87
A computational approach to identify point mutations associated with occult hepatitis B: significant mutations affect coding regions but not regulative elements of HBV. Virol J (2011) 0.86
Hepatocellular carcinoma in African Blacks: Recent progress in etiology and pathogenesis. World J Hepatol (2010) 0.82
Hepatitis B virus DNA splicing in Lebanese blood donors and genotype A to E strains: implications for hepatitis B virus DNA quantification and infectivity. J Clin Microbiol (2012) 0.82
Prevalence and molecular analysis of occult hepatitis B virus infection isolated in a sample of cryptogenic cirrhosis patients in iran. Oman Med J (2014) 0.79
Occult Hepatitis B Virus Infection in Nigerian Blood Donors and Hepatitis B Virus Transmission Risks. PLoS One (2015) 0.78
Characterization of the occult hepatitis B virus variants circulating among the blood donors from eastern India. ScientificWorldJournal (2013) 0.76
Epidemiology, risk factors and genotypes of HBV in HIV-infected patients in the northeast region of Colombia: high prevalence of occult hepatitis B and F3 subgenotype dominance. PLoS One (2014) 0.76
Occult hepatitis B virus infection in HIV positive patients at a tertiary healthcare unit in eastern India. PLoS One (2017) 0.75
Occult Hepatitis B virus infection in previously screened, blood donors in Ile-Ife, Nigeria: implications for blood transfusion and stem cell transplantation. Virol J (2016) 0.75
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol (2010) 5.23
Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell (2007) 3.89
Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol (2008) 3.50
Predonation screening of blood donors with rapid tests: implementation and efficacy of a novel approach to blood safety in resource-poor settings. Transfusion (2005) 3.08
Relative safety of first-time volunteer and replacement donors in West Africa. Transfusion (2009) 2.50
Humanitarian ventures or 'fistula tourism?': the ethical perils of pelvic surgery in the developing world. Int Urogynecol J Pelvic Floor Dysfunct (2006) 2.14
The global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysis. PLoS Med (2009) 2.06
The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell (2007) 2.05
Transfusion-transmitted hepatitis B virus infection. J Hepatol (2009) 1.70
Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med (2011) 1.69
The risk of hepatitis B virus infection by transfusion in Kumasi, Ghana. Blood (2002) 1.66
Frequent recovery and broad genotype 2 diversity characterize hepatitis C virus infection in Ghana, West Africa. J Virol (2003) 1.50
Infectivity of blood products from donors with occult hepatitis B virus infection. Transfusion (2013) 1.43
Identification and characterization of persistent human erythrovirus infection in blood donor samples. J Virol (2004) 1.43
Persistence of HTLV-I in blood components after leukocyte depletion. Blood (2002) 1.39
Persistent B19 infection in immunocompetent individuals: implications for transfusion safety. Blood (2005) 1.39
Blood donor screening for parvovirus B19 in Germany and Austria. Transfusion (2007) 1.35
Multiplex real-time quantitative RT-PCR assay for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus type 1. J Virol Methods (2004) 1.33
Anti-HBs positive occult hepatitis B virus carrier blood infectious in two transfusion recipients. J Hepatol (2008) 1.30
Identification and genetic diversity of two human parvovirus B19 genotype 3 subtypes. J Gen Virol (2007) 1.28
Characterization of occult hepatitis B virus from blood donors carrying genotype A2 or genotype D strains. J Hepatol (2008) 1.25
The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer. J Pathol (2012) 1.24
Impact of hepatitis B virus surface protein mutations on the diagnosis of occult hepatitis B virus infection. Hepatology (2010) 1.23
Maternofetal transmission of hepatitis B virus genotype E in Ghana, west Africa. J Gen Virol (2007) 1.23
Dating the origin and dispersal of hepatitis B virus infection in humans and primates. Hepatology (2013) 1.19
Sensitivity of HCV RNA and HIV RNA blood screening assays. Transfusion (2002) 1.15
Diagnostic algorithm for HBV safe transfusion. Blood Transfus (2009) 1.08
Transfusion in sub-Saharan Africa: does a Western model fit? J Clin Pathol (2007) 1.06
A pool of repeat blood donors can be generated with little expense to the blood center in sub-Saharan Africa. Transfusion (2008) 1.04
Characterization of HBV DNA+/HBsAg- blood donors in Poland identified by triplex NAT. Hepatology (2006) 1.04
Hepatitis C virus and hepatitis B virus bind to heparin: purification of largely IgG-free virions from infected plasma by heparin chromatography. J Gen Virol (2005) 1.03
HIV escape from natural killer cytotoxicity: nef inhibits NKp44L expression on CD4+ T cells. AIDS (2009) 1.03
Simultaneous visual detection of multiple viral amplicons by dipstick assay. J Clin Microbiol (2005) 1.02
Efficacy of hepatitis B virus (HBV) DNA screening and characterization of acute and occult HBV infections among blood donors from Madrid, Spain. Transfusion (2009) 1.00
Molecular epidemiology of HIV in Ghana: dominance of CRF02_AG. J Med Virol (2004) 1.00
Protective effect of HLA-B57 on HCV genotype 2 infection in a West African population. J Med Virol (2007) 1.00
Full genome characterization of hepatitis B virus strains from blood donors in Iran. J Med Virol (2011) 1.00
Characterization of periplasmic protein BP26 epitopes of Brucella melitensis reacting with murine monoclonal and sheep antibodies. PLoS One (2012) 1.00
Head-to-head comparison of two transcription-mediated amplification assay versions for detection of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus Type 1 in blood donors. Transfusion (2013) 0.99
Occult hepatitis B infection in blood donors from South East Asia: molecular characterisation and potential mechanisms of occurrence. Gut (2012) 0.99
Characterization of occult hepatitis B virus strains in South African blood donors. Hepatology (2009) 0.99
Increasing threat of brucellosis to low-risk persons in urban settings, China. Emerg Infect Dis (2014) 0.98
A novel hepatitis B virus subgenotype, D7, in Tunisian blood donors. J Gen Virol (2009) 0.98
External financial aid to blood transfusion services in sub-Saharan Africa: a need for reflection. PLoS Med (2012) 0.98
DiGeorge syndrome critical region 8 (DGCR8) protein-mediated microRNA biogenesis is essential for vascular smooth muscle cell development in mice. J Biol Chem (2012) 0.97
A cluster of human immunodeficiency virus Type 1 recombinant form escaping detection by commercial genomic amplification assays. Transfusion (2010) 0.97
Multiplex real-time PCR for the detection and quantification of latent and persistent viral genomes in cellular or plasma blood fractions. J Virol Methods (2008) 0.97
Evaluation of a new hepatitis B virus surface antigen rapid test with improved sensitivity. J Clin Microbiol (2008) 0.96
Transmissibility of hepatitis B virus (HBV) infection through blood transfusion from blood donors with occult HBV infection. Clin Infect Dis (2011) 0.95
Angiotensin type 2 receptor-mediated apoptosis of human prostate cancer cells. Mol Cancer Ther (2009) 0.95
A probable case of hepatitis B virus transfusion transmission revealed after a 13-month-long window period. Transfusion (2008) 0.94
Prevalence of persistent and latent viruses in untreated patients infected with HIV-1 from Ghana, West Africa. J Med Virol (2009) 0.93
Nucleic acid testing (NAT) in high prevalence-low resource settings. Biologicals (2010) 0.93
Duplex molecular assay intended for point-of-care diagnosis of influenza A/B virus infection. J Clin Microbiol (2013) 0.92
The efficacy of individual-donation and minipool testing to detect low-level hepatitis B virus DNA in Taiwan. Transfusion (2009) 0.92
ß3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells. Mol Cancer (2012) 0.92
Increased prevalence of hepatitis C virus subtype 6a in China: a comparison between 2004-2007 and 2008-2011. Arch Virol (2014) 0.92
Hepatitis B virus (HBV) infection and recombination between HBV genotypes D and E in asymptomatic blood donors from Khartoum, Sudan. J Clin Microbiol (2010) 0.89
Investigating the prevalence of transfusion transmission of Plasmodium within a hyperendemic blood donation system. Transfusion (2012) 0.89
Differential reactivity of putative genotype 2 hepatitis C virus F protein between chronic and recovered infections. J Gen Virol (2008) 0.89
Characterization of occult hepatitis B virus infection from blood donors in China. J Clin Microbiol (2011) 0.89
Antibody detection and kinetics of antibody production during early stages of immunization with hepatitis B virus vaccine. Clin Vaccine Immunol (2007) 0.89
Hepatitis B virus in transfusion medicine: still a problem? Biologicals (2012) 0.88
Deletions and recombinations in the core region of hepatitis B virus genotype E strains from asymptomatic blood donors in Guinea, west Africa. J Gen Virol (2009) 0.87
Nucleic acid dipstick test for molecular diagnosis of pandemic H1N1. J Clin Microbiol (2010) 0.87
Comparison of seven hepatitis B virus (HBV) nucleic acid testing assays in selected samples with discrepant HBV marker results from United States blood donors. Transfusion (2014) 0.86
Higher viral load may explain the dominance of CRF02_AG in the molecular epidemiology of HIV in Ghana. AIDS (2004) 0.86